Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 15/20 | 0.48 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCND2 | P30279 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | EED | O75530 | 1/20 | 0.40 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.40 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.40 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12684492 | 0.88 | EZH2 (0.60) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL18800371 | 0.86 | EZH2 (0.49) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL19391462 | 0.85 | EZH2 (0.45) | EZH2EZH1CDK4CCND1CCND2 | |
| SCHEMBL21418346 | 0.82 | EZH2 (0.55) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12684439 | 0.81 | EZH2 (0.60) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL18800423 | 0.80 | EZH2 (0.53) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL22517657 | 0.79 | EZH2 (0.52) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL18800350 | 0.79 | EZH2 (0.54) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12684211 | 0.77 | EZH2 (0.67) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12498441 | 0.76 | EZH2 (0.65) | EZH2EZH1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EZH1 2661/4885CDK4 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.